Showing results (21-30 of 419) with videos related to
Sort By:
Pageof 42
European Journal of Haematology|August 30, 2017
The management of hodgkin lymphomas in pregnanciesYakir Moshe, Ohad Shimshon Bentur, Michael Lishner, et al.Blood Cells, Molecules & Diseases|January 8, 2015
Impaired migration capacity in monocytes derived from patients with Gaucher diseaseNoam Bettman, Irit Avivi, Hanna Rosenbaum, et al.Journal of Fungi (Basel, Switzerland)|September 28, 2021
Predictors of Early and Late Mortality for Patients with Hematologic Malignancy and Invasive Mold DiseaseEva L Yashphe, Ron Ram, Irit Avivi, et al.Rambam Maimonides Medical Journal|November 12, 2014
Dendritic cell cancer vaccines: from the bench to the bedsideTamar Katz, Irit Avivi, Noam Benyamini, et al.Leukemia & Lymphoma|July 3, 2020
Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimenYuval Neeman, Chava Perry, Barbara Silverman, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 11, 2018
Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myelomaNoa Lavi, Irit Avivi, Zipora Kra-Oz, et al.Applied Clinical Informatics|October 8, 2022
Remote Digital Microscopy Improves Hematology Laboratory Workflow by Reducing Peripheral Blood Smear Analysis Turnaround TimeBen-Zion Katz, Dan Benisty, Yael Sayegh, et al.Cancer Immunology, Immunotherapy : CII|January 18, 2012
Rituximab-induced direct inhibition of T-cell activationDina Stroopinsky, Tamar Katz, Jacob M Rowe, et al.European Journal of Haematology|October 26, 2023
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patientsIrit Avivi, Tamir Shragai, Efrat Luttwak, et al.European Journal of Immunology|July 28, 2009
Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacityDina Stroopinsky, Irit Avivi, Jacob M Rowe, et al.Pageof 42